VCYT is the ticker symbol for VERACYTE, INC., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks VCYT with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is VCYT a good stock to buy?

13F Pro's AI ranking engine scores VCYT at 68.2/100, ranked #318 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for VCYT is available at https://13fpro.ai/company/VCYT. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source VCYT data?

All VERACYTE, INC. fundamentals and ownership data come directly from SEC EDGAR. VERACYTE, INC. files with the SEC under CIK 1384101. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

VERACYTE, INC. VCYT

NasdaqMid CapHealthcare

13F Pro quality score

Rank #318 of 2,925TOP 25%

Why it scores 68 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$150.32M

Quarter to Jun 30

Net income

$25.49M

Quarter to Jun 30

Free cash flow

$42.97M

Quarter to Jun 30

Operating margin

15.3%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$5.22B total

BlackRock, Inc.

$792.06M+2.4%

FMR LLC

$452.38M-0.8%

Artisan Partners Limited Partnership

$325.27M+0.8%

VANGUARD PORTFOLIO MANAGEMENT LLC

$276.98M+6.1%

STATE STREET CORP

$275.95M-6.8%

VANGUARD CAPITAL MANAGEMENT LLC

$211.07M+1.7%

DIMENSIONAL FUND ADVISORS LP

$166.01M-1.9%

FIRST TRUST ADVISORS LP

$147.29M+18.5%

ARK Investment Management LLC

$134.84M-24.8%

WELLINGTON MANAGEMENT GROUP LLP

$133.56M-11.1%

GEODE CAPITAL MANAGEMENT, LLC

$123.59M+7.5%

GOLDMAN SACHS GROUP INC

$96.49M+28.7%

FULLER & THALER ASSET MANAGEMENT, INC.

$88.67M+6.7%

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC

$84.08M+44.7%

GW&K Investment Management, LLC

$83.19M-1.4%

MORGAN STANLEY

$69.99M+49.4%

BANK OF AMERICA CORP /DE/

$64.74M-23.9%

DRIEHAUS CAPITAL MANAGEMENT LLC

$61.42MNew

NORTHERN TRUST CORP

$58.50M+7.2%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$55.21M+1.8%

OBERWEIS ASSET MANAGEMENT INC/

$51.55M+4.5%

Legal & General Group Plc

$50.40M-4.4%

Sumitomo Mitsui Trust Holdings, Inc.

$45.16M-27.2%

Nikko Asset Management Americas, Inc.

$45.12M-26.4%

Point72 Asset Management, L.P.

$43.33M+52.5%

See all 371 institutional holders →

What's Driving VCYT's Business? Latest 10-Q Breakdown

29/29 datapoints verified

AI-extracted from the 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Veracyte grew Q2 FY2026 revenue 15% YoY to $150.3M on 19% testing revenue growth and swung to $23.0M operating income from a $5.3M operating loss a year earlier.

Biggest Revenue Drivers

Testing revenue$145.7M+19% YoY

Driven by a 14% volume increase, improved ASP, and prior period collections

Product revenue$3.9M+7% YoY

Primarily international sales of the Prosigna breast cancer IVD kit

Biggest Revenue Drivers

Total revenue: $150.3M+15% YoY

Testing revenue$145.7M+19% YoY

Driven by a 14% volume increase, improved ASP, and prior period collections

Product revenue$3.9M+7% YoY

Primarily international sales of the Prosigna breast cancer IVD kit

Biopharmaceutical and other revenue$0.8M-81% YoY

Discontinuation of biopharmaceutical, contract manufacturing and development services previously conducted in France following Veracyte SAS restructuring

Largest Expense Items

Cost of testing revenue$36.3M+12% YoY

Increased testing volume, higher staffing for volume and new test launches, and infrastructure buildout, partly offset by lab efficiencies

Research and development$29.4M+81% YoY

$6.5M shift of software development expenses from G&A now fully dedicated to product development, plus added headcount and merit increases

Selling and marketing$28.3M+12% YoY

Annual compensation increases, headcount additions, and tradeshow/new test launch costs

General and administrative$27.4M-15% YoY

Reassignment of software development costs to R&D and customer service costs to cost of revenue, plus lower legal, audit and tax fees

Margins: Gross profit rose 21% YoY to $108.5M as cost of revenue grew just 3% versus 15% revenue growth. Operating income reached $23.0M versus a $5.3M loss a year earlier, aided by the absence of the prior year's $20.5M non-cash impairment charge.

Watch Items from the Filing

Medicare and UnitedHealthcare together represented 46% of total revenue in Q2 2026 (33% and 13%, respectively), a significant payer concentration.
Veracyte's patent infringement suit against Sonic Healthcare USA over ThyroSeq v3 cleared a motion to dismiss, but the USPTO granted an ex parte reexamination of one asserted patent on July 21, 2026; jury trial set for Q1 next year.
R&D expense grew 81% YoY as spending shifted toward TrueMRD platform development and new IVD products, a step-up in investment ahead of any related revenue.
Cash, cash equivalents and short-term investments rose to $485.2M, up $72.3M in the first half of 2026, supported by $81.0M of operating cash flow.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/VCYT

Earnings Per Share

13fpro.ai/company/VCYT

Loading ratio trend…

About VERACYTE, INC. (VCYT): stock profile, AI score and financials

VERACYTE, INC. (VCYT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VCYT at 68.2/100 on a composite quality score built from its SEC filings, placing it at rank #318 of 2,925 stocks — the top 25% of the AI-ranked universe. VCYT scores in the top quartile across profitability (84.2), free cash flow (83.9), balance sheet strength (80.9). Areas of concern include institutional flow (32.9) and revenue scale (38.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), VERACYTE, INC. reports quarterly revenue of $150.3M, net income of $25.5M, an operating margin of 15.3%. VCYT trades on the Nasdaq exchange and files with the SEC under CIK 1384101. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VCYT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VERACYTE, INC. directly from SEC EDGAR.

SEC EDGAR: CIK 1384101 →

VERACYTE, INC. VCYT

Top Institutional Holders

What's Driving VCYT's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

VCYT insiders

Congress trading in VCYT

About VERACYTE, INC. (VCYT): stock profile, AI score and financials

VERACYTE, INC. VCYT

Top Institutional Holders

What's Driving VCYT's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

Companies similar to VCYT

VCYT insiders

Congress trading in VCYT

About VERACYTE, INC. (VCYT): stock profile, AI score and financials